Background: Irinotecan and temozolmide achieve objective responses in
patients with Ewing sarcoma which recurrences after initial therapy.
Optional dose schedules have not been defined. Procedure: We reviewed
published series of patients treated with irinotecan and temozolomide
for Ewing sarcoma which recurred after initial therapy. We compared
objective response rates for patients who received 5 day irinotecan
treatment schedules to response rates for patients who achieved 10 day
irinotecan treatment schedules. Results: Among 94 patients treated with
a 10 day irinotecan schedule there were 48 objective responses (51%).
Among 218 patients treated with a 5 day irinotecan schedule there were
65 responses (30%). Conclusion: When we use irinotecan to treat Ewing
sarcoma we should administer 10 days of treatment.